The Angeles Clinic and Research Institute
Santa Monica, California, 90404, United States
NCT Number: NCT01011530
This is an open-label, multicenter, phase 1, dose escalation study that will evaluate the safety profile, establish Maximum Tolerated Dose (MTD), and inform the recommended phase 2 dose of MLN4924 as well as evaluate antitumor activity in patients with metastatic melanoma.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Santa Monica, California, 90404, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Each patient must meet all of the following criteria to be enrolled in the study:
Exclusion criteria
Patients meeting any of the following exclusion criteria are not to be enrolled in the study:
Patients will be administered MLN4924 via an IV infusion. Each 21-day treatment cycle is composed of 2 weeks intermittent dosing of MLN4924 on Days 1, 4, 8 and 11, followed by a rest period of 10 days. A cohort of patients will receive a reduced first dose on Day 1, approximately half the strength of the dose received on Days 4, 8, 11 and dose will not be administered on Day 4 if the Day 1 dose is not tolerated.(Schedule A ramp-up), or continuous weekly dosing (Days 1, 8, and 15) of MLN4924 (Schedule B)
Time frame: Up to 12 months of treatment
Time frame: Up to 12 months of treatment
Time frame: Primarily assessed during the first cycle of therapy
Millennium Pharmaceuticals, Inc.
Industry
A Phase I, Open-Label, Dose Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Melanoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03225365
Melanoma, Metastatic Melanoma
Pierre-Bénite, France
View Trial DetailsNCT02073123
Melanoma, Metastatic Melanoma
Augusta, Georgia, United States
View Trial DetailsNCT06151847
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma
Kansas City, Kansas, United States
View Trial DetailsNCT05704933
Brain Diseases, Brain Neoplasms
Tampa, Florida, United States
View Trial Details